Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Frontier Medicines | 2024 | Series C | Undisclosed | San Francisco |
| Ollin Biosciences | 2026 | Series B | $100.0M | Austin |
| Taysha Gene Therapies | 2026 | Post-IPO Equity | Undisclosed | Dallas |
| Helus Pharma | 2026 | Post-IPO Equity | Undisclosed | Toronto |
| Aurinia Pharmaceuticals | 2026 | Post-IPO Equity | Undisclosed | Victoria |
| Contraline | 2026 | Series B | Undisclosed | Charlottesville |
| Dyne Therapeutics | 2026 | Post-IPO Debt | Undisclosed | Cambridge |
| Legend Biotech | 2026 | Post-IPO Equity | Undisclosed | Piscataway |
| Moderna | 2026 | Grant | Undisclosed | Cambridge |
| Parabilis Medicines | 2026 | Post-IPO Equity | $305.0M | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Frontier Medicines | Series C | Undisclosed | San Francisco, United States |
| 27 | Ollin Biosciences | Series B | $100.0M | Austin, United States |
| 28 | Taysha Gene Therapies | Post-IPO Equity | Undisclosed | Dallas, United States |
| 29 | Helus Pharma | Post-IPO Equity | Undisclosed | Toronto, Canada |
| 30 | Aurinia Pharmaceuticals | Post-IPO Equity | Undisclosed | Victoria, Canada |
| 31 | Contraline | Series B | Undisclosed | Charlottesville, United States |
| 32 | Dyne Therapeutics | Post-IPO Debt | Undisclosed | Cambridge, United States |
| 33 | Legend Biotech | Post-IPO Equity | Undisclosed | Piscataway, United States |
| 34 | Moderna | Grant | Undisclosed | Cambridge, United States |
| 35 | Parabilis Medicines | Post-IPO Equity | $305.0M | Cambridge, United States |
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Contraline is a clinical-stage biotechnology company that develops male contraceptive solutions.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.
Moderna Therapeutics is a biotechnology company that develops medicines and vaccines based on messenger RNA (mRNA) technology.
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
SonoThera develops ultrasound-based technologies for delivering genetic therapies to targeted tissues.
Exo is a medical device startup which develops handheld ultrasound devices and AI for imaging and therapeutic applications.
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Secretome Therapeutics is a clinical-stage cell therapy company that develops therapies for rare cardiac diseases.
Pluton Biosciences tests and discovers microbes for the production of a variety of products, primarily pesticides, and pharmaceuticals.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
RA Capital Management has invested in 369 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 17 different industry categories.
Among tracked funding rounds, Parabilis Medicines received $305.0M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 369 companies.
Recent RA Capital Management portfolio additions include Frontier Medicines, Ollin Biosciences, Taysha Gene Therapies, Helus Pharma, Aurinia Pharmaceuticals. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors